Medical Real Estate, Research and Diagnostic Substances

May 07, 2015

Buy ($175)

Topics covered: Strong Performance by Diversified Diagnostics Companies, Large Health Care REITs, Lagging Diagnostics Space, Health Care REIT Earnings Growth, Diagnostics and Lab Services, Consolidation in the REIT Sector

Companies covered: Cytori Therapeutics Inc (NASDAQ:CYTX), Ventas, Inc. (NYSE:VTR), Taubman Centers, Inc. (NYSE:TCO), Simon Property Group, Inc. (NYSE:SPG), Omega Healthcare Investors, Inc. (NYSE:OHI), Macerich Company (The) (NYSE:MAC), Health Care REIT, Inc. (NYSE:HCN), HCP, Inc. (NYSE:HCP), Meridian Bioscience Inc. (NASDAQ:VIVO), Myriad Genetics, Inc. (NASDAQ:MYGN), Laboratory Corporation of America Holdings (NYSE:LH), Quest Diagnostics Incorporated (NYSE:DGX), DARA Biosciences, Inc. (NASDAQ:DARA)